Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.
Eleutherakis-Papaiakovou E, Dimopoulos MA, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E. Eleutherakis-Papaiakovou E, et al. Among authors: terpos e. Bone Marrow Transplant. 2017 Nov;52(11):1537-1542. doi: 10.1038/bmt.2017.172. Epub 2017 Aug 14. Bone Marrow Transplant. 2017. PMID: 28805791
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A. Terpos E, et al. Bone Marrow Transplant. 2003 Feb;31(3):163-70. doi: 10.1038/sj.bmt.1703818. Bone Marrow Transplant. 2003. PMID: 12621476
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsonis MC, Panayiotidis P, Maniatis A; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: terpos e. Ann Oncol. 2003 Jul;14(7):1039-44. doi: 10.1093/annonc/mdg287. Ann Oncol. 2003. PMID: 12853344 Free article. Clinical Trial.
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, Dimopoulos MA, Zervas K. Terpos E, et al. Leukemia. 2005 Nov;19(11):1969-76. doi: 10.1038/sj.leu.2403890. Leukemia. 2005. PMID: 16079895 Clinical Trial.
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsonis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos MA; Greek Myeloma Study Group. Zervas K, et al. Among authors: terpos e. Ann Oncol. 2007 Aug;18(8):1369-75. doi: 10.1093/annonc/mdm178. Ann Oncol. 2007. PMID: 17693650 Free article. Clinical Trial.
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A. Dimopoulos MA, et al. Among authors: terpos e. Ann Oncol. 2009 Jan;20(1):117-20. doi: 10.1093/annonc/mdn554. Epub 2008 Aug 9. Ann Oncol. 2009. PMID: 18689864 Free article.
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. Terpos E, et al. Leukemia. 2008 Dec;22(12):2247-56. doi: 10.1038/leu.2008.235. Epub 2008 Sep 4. Leukemia. 2008. PMID: 18769451 Clinical Trial.
746 results